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An outbreak of coronavirus disease 2019 (COVID-19) emerged in China in
December 2019 and spread so rapidly all around the globe. It’s continued and
spreading more dangerously in India and Brazil with higher mortality rate.
Understanding of the pathophysiology of COVID-19 depends on unraveling of
interactional mechanism of SARS-CoV-2 and human immune response. The
immune response is a complex process, which can be better understood by
understanding the immunological response and pathological mechanisms of
COVID-19, which will provide new treatments, increase treatment efﬁcacy, and
decrease mortality associated with the disease. In this review we present a
amalgamate viewpoint based on the current available knowledge on COVID-19
which includes entry of the virus and multiplication of virus, its pathological
effects on the cellular level, immunological reaction, systemic and organ
presentation. T cells play a crucial role in controlling and clearing viral
infections. Several studies have now shown that the severity of the COVID19 disease is inversely correlated with the magnitude of the T cell response.
Understanding SARS-CoV-2 T cell responses is of high interest because T cells
are attractive vaccine targets and could help reduce COVID-19 severity. Even
though there is a signiﬁcant amount of literature regarding SARS-CoV-2, there
are still very few studies focused on understanding the T cell response to this
novel virus. Nevertheless, a majority of these studies focused on peripheral
blood CD4+ and CD8+ T cells that were speciﬁc for viruses. The focus of this
review is on different subtypes of T cell responses in COVID-19 patients, Th17,
follicular helper T (TFH), regulatory T (Treg) cells, and less classical, invariant T
cell populations, such as dg T cells and mucosal-associated invariant T (MAIT)
cells etc that could inﬂuence disease outcome.
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populations, such as the gdT cells and mucosal-associated
invariant T cells (MAIT), may also be vital in the process,
particularly in certain tissues such as the lung.
As a result of the emergence of SARS-CoV-2 variants that
have the ability to evade antibodies, the ﬁrst-generation COVID19 vaccines have proven effective in mitigating severe illness and
hospitalization, but recurring waves of infections lead to
diminishing vaccine effectiveness. A study suggested that as a
result of intestinal or parenteral immunization, viruses were
controlled effectively and lung pathology was prevented,
regardless of neutralizing antibodies present. When antibodies
effectively neutralized the challenge virus, mucosal memory CD8
T cells provided little protection. When CD8 T cells were
“unhelped” or not accompanied by CD4 T cells and
neutralizing antibodies, mucosal memory CD8 T cells
provided no protection against homologous SARSCoV-2.
Nevertheless, memory CD4 and “helped” CD8 T cells in the
lung, in the absence of detectable virus-neutralizing antibodies,
provided signiﬁcant protection against the antibody-resistant
B1.351 (b) variant, without causing lung immunopathology
(Kingstad-Bakke et al., 2022).
A c o m p r e h e n s i v e u n d e r s t a n d i n g o f CO V I D - 1 9
immunopathogenesis will contribute to the design of a
satisfactory treatment for SARS-CoV-2 infection. The purpose
o f t h i s r e v i e w i s t o g i v e a br i e f o v e r v i e w o f th e
immunopathogenesis of COVID-19 infection, along with the
conventional and unconventional T cell immune responses,
which can be used to target the dysregulated immune response
in COVID-19 infection.

Introduction
There is ongoing outbreak of COVID-19, a novel
coronavirus disease caused by SARS-CoV-2) emerged in China
in December 2019 (Gates, 2020). The SARS-CoV-2 infection can
manifest in a wide range of clinical manifestations, which can
range from asymptomatic to mild COVID-19 infections, even
severe COVID-19 infections which are hospital-acquired. When
a patient is hospitalized, the likelihood of developing severe
pneumonia, or the development of acute respiratory distress
syndrome (ARDS), is very high (Yang et al., 2020). Presently,
there are no effective antiviral drugs speciﬁcally designed to treat
SARS-CoV-2 infection. Recent studies have provided important
insights into the immune responses of patients who are
hospitalized, even though relatively little is known about the
immunology of asymptomatic or mild disease individuals
(Oxenius and Zajac, 2022). According to current research, the
adaptive immune system contributes a great deal to the
progression of SARS-CoV-2 infection in a similar way as with
any other respiratory viral infection (Bhardwaj et al., 2022).
There is still some uncertainty regarding whether T-cell
responses are useful or harmful in COVID-19, as well as
whether they are suboptimal, dysfunctional, or excessive.
There are studies that show evidence for both ends of the
spectrum (de Candia et al., 2021; Luo et al., 2021; Toor
et al., 2021).
In order to fully understand the pathogenesis of COVID-19,
we need to know a pivotal role is played by the immune system.
Both innate and adaptive immune responses need to be activated
in a coordinated manner to eliminate the SARS-CoV-2 infection.
The uncontrolled innate immune responses and compromised
adaptive immune responses, resulting in widespread tissue
destruction in COVID-19 infection. There are several clinically
approved anti-viral drugs available for the treatment of COVID19 infection, but they are not very promising. It is well known
that T cells play an important role in controlling and preventing
viral infections onset and spread (Bhardwaj et al., 2022). As a
matter of fact, it has been demonstrated that COVID-19 disease
severity inversely correlates with the magnitude of T cell
response in several recent studies (Chen and John Wherry,
2020). In order to assist COVID-19 patients in decreasing the
severity of their illness, it is of great interest to understand how T
cells are responding to SARS-CoV-2 as they are attractive
vaccine targets. There is a tremendous amount of literature
that deals with SARS-CoV-2 speciﬁc research, however, studies
speciﬁcally designed to understand how T cells are responding to
this novel virus are relatively few in number. The majority of
these studies are nonetheless focused on peripheral T cells that
are speciﬁc for viruses as well as CD8+ T cells. The signiﬁcance
of other T cell subtypes should not be underestimated, however.
For example, the role of follicular helper T (TFH), regulatory T
(Treg) cells, Th17 as well as less classical, invariant T cell
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Pathogenesis and cytokine storm
in COVID-19
SARS-CoV-2, is a single strand virus, is transmitted from
infected patients to healthy individuals via direct contact or by
spreading respiratory droplets (Rothan and Byrareddy, 2020).
COVID-19 symptoms that accompany the infection include
fever, cough, pain, weakness, tightness in the chest, loss of
taste and smell, as well as dyspnea, all of which are associated
with acute respiratory distress syndrome (ARDS) (Huang et al.,
2020). Hypoxemia, difﬁculty breathing, and onset of pulmonary
edema are a few of the symptoms of ARDS, a condition that
leads to respiratory failure by damaging lung endothelium and
alveolar epithelium (Matthay et al., 2019). Both SARS-CoV2 and
SARS-CoV1 are likely able to bind to the angiotensin converting
enzyme 2 (ACE2) present in the lungs as well as other organs
(Hoffmann et al., 2020). Ampliﬁcation of the virus and its
migration down through the conducting airways triggered a
more robust innate immune response, which eventually spreads
down the respiratory tract (Figure 1). As a result of viral
infection, an immune response is triggered which occurs
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FIGURE 1

The following schematic diagram illustrates the steps taking place during the infection and replication of SARS-CoV-2 into host cells: (A) SARS-CoV2 enter into the cell by binding to the ACE2 receptor present on the host cell membrane. As the virus replicates in the lung cells, it induces
pyroptosis and the release of DAMPs (disease associated molecular patterns). Several pro-inﬂammatory cytokines and chemokines, including IL-6,
IL-10, MIP1-a, MIP1-1b, and MCP-1, are secreted by adjoining epithelial cells, alveolar macrophages, and endothelial cells in response to contact
with DAMPs. As a result of these cytokines and chemokines, monocytes, macrophages, and neutrophils are recruited to the lung, thereby releasing
more inﬂammatory cytokines in the process, which cause hypoxia, ﬂuid accumulation in lung, fever and acute lung injury (B) SARS-CoV-2 enters
the cytoplasm and releases viral RNA, which is translated into polyproteins after entering the cytoplasm. The (+) stand genomic RNA is used as a
template to begin replication transcription. Nucleoprotein complexes are formed from sub genomic RNA synthesized by transcription and the (+)
strand genomic RNA. Virions are released from host cells following assembly of nucleoprotein complexes and proteins.

immune system is dysregulated, disrupting the balance of
immunity (Perlman and Dandekar, 2005).
SARS-CoV-2 can be detectable through nasal swabs or
sputum. The cytokine release syndrome (CRS) may lead to
death among COVID-19-infected patients due to a substantial
immune response characterized by abnormal cytokine
production.” Several cytokines and chemokines participate in
the “cytokine storm” in COVID-19 patients (Ragab et al., 2020),
including IL-6, IL-1b, CXCL10, IL-2, IL-10, TNF-a and IFN-g,
but IL-6 plays an especially critical role, for its increased level in
patients’ serum has been associated with respiratory failure,
ARDS, and adverse clinical outcomes (Bhardwaj et al., 2022).
This dysregulation of immune system and cytokine storm causes

through the activation of innate immune cells that identify
pathogen-associated molecule patterns. When the innate
immune system fails to eliminate the virus, the adaptive
immune system comes into play in order to ﬁght the infection.
When innate immune cells and adaptive immune cells are
induced, their secretion of cytokines such as IL-6, IFN-g,
interferon-g-induced protein-10 (IP-10) and monocyte
chemoattractant protein-1 (MCP-1) begins. The cytokines and
chemokines induce the inﬂux of monocytes/macrophages and
neutrophils at the site of infection from the bloodstream
(Bhardwaj et al., 2022). Viral infection is cleared by the
secretion of cytotoxic substances by these cells. It is normal for
this response to be able to eliminate the virus, but sometimes the
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characterized. However, few studies have examined T cell
immunity and here we are discussing the advancement of T
cell response to SARS-CoV-2.
CD4+ and CD8+ T cells in COVID-19 infection:
Lymphopenia (a decrease in lymphocyte numbers), one of the
symptoms of SARS-CoV-2 infection, is characteristic of severe
infection. Several studies have suggested that disease intensity is
correlated with lymphopenia, and it occurs more frequently in
those with a higher mortality rate, particularly in severe cases
(Tavakolpour et al., 2020). A pronounced decrease in CD4+ T
cells, CD8+ T cells, and B cells has been reported in COVID-19
patients (Chen and John Wherry, 2020; Zhou et al., 2020). It is
currently unknown how lymphopenia occurs in COVID-19, but
it is known that most patients with severe disease have decreased
T cell numbers, speciﬁcally CD8+ T cells, however the reason is
unclear (Tavakolpour et al., 2020). Infections with other
respiratory viruses, including inﬂuenza, have been associated
with lymphopenia (McClain et al., 2013).
PD-1, a marker for exhausted T cells, appeared to be
signiﬁcantly more abundant in COVID-19 patients. As patients
progressed from prodromal to overtly symptomatic stages, they
expressed more PD-1 and Tim-3 on T cells (Diao et al., 2020).
However, people with mild symptoms typically present with a
slightly higher or normal T-cell count than those with moderate
symptoms (Vabret et al., 2020). Even though peripheral T-cell loss
in moderate to severe COVID-19, as well as other viral infections,
is a phenomenon observed in other conditions, its cause remains
elusive, and its cause is not yet certain, unlike MERS-CoV, where
direct viral infection of T cells has been reported (Chu et al., 2016).
According to recent research ﬁndings, the reduction in number of
T cells in the blood may be a result of multiple mechanisms,
including effects caused by inﬂammatory cytokines in the blood.
IL-6, IL-10, and TNF-a seem to correlate with lymphopenia,
while convalescent patients showed lower IL-6 and IL-10 levels,
respectively (Diao et al., 2020; Liu et al., 2020). IFN-a and TNF-a
can inhibit T cell recirculation, as they promote T cell adhesion to
endothelial cells and retention in lymphoid tissues (Shiow et al.,
2006). Chen et al. analyzed the spleens and hilar lymph nodes of
COVID-19-suspected patients following autopsy and observed
extensive lymphocyte death. They suggested that IL-6 and FasFasL interactions mediated apoptosis could be involved in the
development of lymphocytopenia. It was found that tocilizumab,
an IL-6 receptor antagonist, increases circulating lymphocytes in
support of this hypothesis (Giamarellos-Bourboulis et al., 2020).
Similarly, the presence of T cells in the peripheral circulation may
be affected by their recruitment to infection sites. After death from
ARDS brought about by SARS-CoV-2 infection, a post-mortem
examination of the lung showed extensive lymphocyte inﬁltration
further supporting this hypothesis (Xu et al., 2020).
SARS-CoV-2 infection hosts a CD4+ T cell response that can
be impaired, activated excessively, or inappropriately and how
this is corelated to disease outcome is an important question yet
to be explored. When patients recover from COVID-19, they

inﬁltration of neutrophils/monocytes, activation of T cells etc
which cause accumulation of ﬂuids in lungs, increases vascular
permeability and leakage, increase c reactive proteins in liver and
ultimately multi-system organ failure in COVID-19 patients.
CRS plays a major role in the deterioration of COVID-19
patients, from pneumonia through acute respiratory distress
syndrome (ARDS), cumulating in systemic inﬂammation. As a
result of SARS-CoV-2 infection, dendritic cells are delayed in
activation, resulting in impaired T-cell response (Zhou
et al., 2020).

Where does T cell stand to ﬁght
with SARS-CoV-2 infection?
Several variants of SARS-CoV-2 have been identiﬁed which
reduce the ability of antibodies to block infection, posing
concern that we will not be able to stop the disease. T cells are
a critical aspect of the adaptive immune response. Although
anti-viral antibodies can protect cells from infection, when
antibody titer drop by the time after the infection or
vaccination - some cells will ineluctably become infected. In
such a scenario, T cells can help as cytotoxic T cells recognize
infected cells and kill them. Major histocompatibility molecules
on the plasma membrane present viral peptides to T cells so that
they can detect infected cells and viral proteins may be used to
make these T cell peptides. Conversely, only speciﬁc viral
proteins, such as spike, can generate antibodies that block
infection. In past years, the T cell response to SARS-CoV-2
infection has been well studied. The vaccine makers have
dutifully included tests for neutralizing antibodies alongside
the T cell responses in patients that some researchers have
studied (Tea et al., 2021; Li et al., 2022). Although T cells are
important for resolving most viral infections, they have never
been included in the dialogue. They can help prevent and end
disease through their ability to kill virus-infected cells.
The immune system relies on T cells to respond to viral
infections, just as B cells produce antibodies (Swain et al., 2012).
Epithelial cells in the airways are infected by the SARS-CoV-2
virus and it replicates within the cells, using the biochemical
machinery of the host cells. Damage-associated molecules are
being released as a result of programmed cell death of the host
cell (Tay et al., 2020). When these molecules are recognized by
macrophages and nearby endothelial and epithelial cells, they
produce pro-inﬂammatory cytokines (IL-6, TNF-a, IL-1b, IFNg etc), such as chemokines (CXCL10, MCP-1, MIP-1a and 1b
Figures 1, 2). By triggering the release of chemokines and other
cytokines, monocytes, macrophages, and T cells are recruited to
the site of infection, leading to increased inﬂammation. This
inﬂammation is triggered by the production of IFN-g by
recruited T cells (Bhardwaj et al., 2022). To understand disease
pathogenesis, T cell immunity to SARS-CoV-2 must be

Frontiers in Cellular and Infection Microbiology

04

frontiersin.org

Tarique et al.

10.3389/fcimb.2022.964265

FIGURE 2

Recruitments of immune cells and damage of Lung epithelium and cytokine storm: SARS-CoV-2 enter into the cell by binding to the ACE2
receptor present on the host cell membrane. As the virus replicates in the lung cells and damage lung epithelium. Damaged lung epithelium cell
secretes inﬂammatory signals and immune cells recruited in lung blood vessels which secrete pro-inﬂammatory cytokines and chemokines,
including IL-6, IL-10, MIP1-a, MIP1-1b, and MCP-1, are secreted by adjoining epithelial cells, alveolar macrophages, and endothelial cells. As a
result of these cytokines storm happens and increased blood vessels permeability, accumulation of ﬂuid in the lung, hypoxia and ultimately
acute respiratory distress syndrome (ARDS) and multiple organ failure.

have reported signs of possibly exhausted T cells, other studies
have shown an overly aggressive response by CD8+ T cells or
high levels of activated CD8+ T cells with an increased cytotoxic
response in patients with COVID-19 (Chen and John Wherry,
2020). Patients with mild disease had a higher proportion of
CD8+ T cell responses, suggesting that CD8+ T cell responses
may act as a protective factor (Peng et al., 2020). CD8+ T cell
responses were predominantly directed against viral internal
proteins rather than spike proteins, which would be an
important element to consider when developing vaccines
(Peng et al., 2020). A majority of SARS-CoV-2-recovering
patients have CD8+ T cells that are speciﬁc for the virus
(Grifoni et al., 2020). This indicates that there has been a
highly speciﬁc CD8+ T cell response to the virus and that
there is a long-lasting memory of these cells. Nevertheless, it
remains to be seen whether these cells are sufﬁciently able to
protect against future infections. It has been suggested that 40-

often exhibit strong and speciﬁc CD4+ T cell responses that are
similar to what has been seen with inﬂuenza virus infection (Lee
and Crane, 1988). Within days of onset of symptoms during
acute COVID-19 infection, the frequency of SARS-CoV-2–
speciﬁc CD4 T cells increase, leading to an increase in CD4 T
cell activity (Sattler et al., 2020). There have been studies
showing that some patients with severe COVID-19 have
impaired CD4+ T cell function, which includes lowered IFN-g
production (Sattler et al., 2020). Other researchers believe the T
cells have been over-activated (Mathew et al., 2020). A study
suggested that patients recovered from SARS- CoV-2 had
circulating virus-speciﬁc CD4+ T cells, which suggests T cell
memory and immunity that may last a long time (Grifoni et al.,
2020). There was also some evidence from some studies that
CD8+ T cells from patients with COVID-19 had reduced
cytokine production in response to in vitro stimulation from
patients with severe COVID-19. Considering that some studies
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receptors, but they lack CCR7 chemokine receptors. These cells
also expressed CD45RO, a transcriptional repressor, and a
repressor called Bcl-6 (Crotty, 2014). A Tfh cell’s function is to
act on speciﬁc cells within the immune system such as B-cells by
recognizing CD40L and other costimulatory molecules, in
addition to local cytokines like IL-21 (Elgueta et al., 2009).
While the majority of Tfh cells reside in lymphoid GCs,
circulating Tfh cells (cTfh) circulate in the bloodstream. It is
estimated that about 10% of the total CD4 cell population in the
bloodstream consists of cells expressing CXCR5, similar to the
CXCR5 found in lymphoid tissue. Circulating T follicular helper
cells (cTfh), deﬁned as CXCR5+PD1+ CD4 T cells (Jandl et al.,
2017). The activation of cTfh cells leads to the production of low
levels of cytokines such as IFN-g, IL-4, and IL-17 (Wang
et al., 2016).
A certain subset of activated cTfh cells is seen in the
bloodstream of those who are infected with SARS-CoV-2, or
who have been vaccinated against it for a short period of time.
The CD4 T-cells contribute to the immune response to antigens
in vaccines or viruses (Cui et al., 2021). Therefore, activation of
cTfh cells indicates a healthy and normal immune response to
virus antigens. It is important to note, however, that different
subsets of cTfh tend to be associated with different antibody
production functions (Koutsakos et al., 2022). COVID-19 is
characterized by the activation of a subset of cTfh cells with
reduced CCR7 expression, high expression of PD-1 and high
expression of ICOS-1 expression, which remains active for up to
two weeks after symptoms occur (Gong et al., 2020). An acute
infection usually results in the emergence of cTfh cells speciﬁc
for the S protein, and these cells persist for six months or more
(Salinas et al., 2021). A signiﬁcant reduction in the number of
cTFH cells that express CXCR3–CCR6+ was seen in the late
stage of disease compared with the acute stage or early
convalescence (Balachandran et al., 2022). Nonetheless,
COVID-19 patients who have recovered have shown antigenspeciﬁc cTfh cells are able to produce IL-21 and IFN-g. In acute
COVID-19, the cTfh activation is used as a measure of the titer
and avidity of the anti-RBD IgM antibodies (Juno et al., 2020).
Similarly, high anti-anti-S antibody levels are observed in cTfh1
cells expressing CXCR3. As a matter of fact, the frequency of
cTfh cells that are reactive with the SARS-CoV-2 S, N, and M
antigens correlates with the number of neutralizing titers (Juno
et al., 2020). There is some evidence that severe COVID-19 is
associated with a reduction in the frequency of Tfh cells, with a
higher frequency of cytotoxic cTfh cells expressing granzyme B
and perforin (Kalfaoglu et al., 2021). It has been observed that
current mRNA-based vaccines induce robust GC responses,
which are accompanied by spike-speciﬁc activation of cTfh
cells. It is known that these cells produce IFN-g but not IL-17
while they peak at one month and then wane (Goel et al., 2021).
T regulatory cells in COVID-19: The regulatory T cells
(Tregs) represent 5–10% of CD4+ T cells and express FoxP3
transcription factor and CD25, which play a critical role in

60% of unexposed people have T cells that are reactive to SARSCoV-2, a ﬁnding that supports the suggestion that circulating
‘common cold’ coronaviruses have shared similar recognition
patterns with SARS-CoV-2 (Grifoni et al., 2020). An additional
study reported cross-reactive memory T cells in patients who
had recovered from SARS-CoV 17 years ago, as well as in
individuals who had not suffered from SARS before (Le Bert
et al., 2020). There have also been detectable SARS-CoV-2speciﬁc memory T cells detected in seronegative healthy
individuals who have been exposed to conﬁrmed cases,
suggesting an asymptomatic infection. The results of one study
show that during the acute phase of the disease, SARS-CoV-2speciﬁc T cells exhibited a high level of cytotoxicity, and a stemlike memory phenotype was observed in SARS-CoV-2-speciﬁc T
cells in the convalescent phase (Sekine et al., 2020). Convalescent
patients were found to have T cells speciﬁc for SARS-CoV-2 in
most of the cases. This may be a sign that infection may trigger
development of immunity to COVID-19 (Canete and
Vinuesa, 2020).
GM-CSF-producing CD4+ T helper cells are identiﬁed as a
distinct subset of CD4+ T cells. When activated, these T cells can
recruit inﬂammatory myeloid cells to inﬂammation sites to
enhance the immune response (Zhang et al., 2013). The
presence of pathogenic CD4 cells that express GM-CSF and
IL-6 is associated with the severity of COVID-19 disease. A
higher number of CD4+ cells expressing GM-CSF and IL-6 was
reported in COVID-19 patients admitted to intensive care units
(Zhou et al., 2020). Zhao et al; observed that tissue-resident
memory-like Th17 cells (Trm17 cells) remained in the lungs
after the virus had been eradicated. Trm17 cells expressed CSF2
(GM-CSF) and IL17A, two potential pathogenic cytokines. The
results of an interactome analysis suggest that Trm17 cells
interact with lung macrophages and cytotoxic CD8+ T cells,
which have been known to contribute to the severity of disease
and the damage to the lungs. COVID-19 patients with higher
serum levels of IL-17A and GM-CSF had more severe clinical
symptoms (Zhao et al., 2021). Low GM-CSF levels are essential
for long-term macrophage maintenance and alveolar
macrophage development under homeostatic conditions. As
COVID-19 progresses, increased GM-CSF levels may
contribute to the activation of monocytes and macrophages as
well as the induction of proinﬂammatory cytokines and
contribute to the T cell-mediated acute pulmonary
inﬂammation. Through increased GM-CSF levels in
bronchoalveolar ﬂuid, acute respiratory distress syndrome may
be indirectly caused by a reduction in neutrophil apoptosis,
which contributes to microvascular damage (Mu et al., 2021).
Follicular helper T (TFH) cells response in COVID-19: It is a
special subset of CD4+ T cells that can help in enhancing the
function of B cells by providing assistance through both cell-cell
interactions as well as cytokine release, which helps improve the
effectiveness of B cells resulting in antibodies being produced
(Swain et al., 2012). The cells in Tfh express CXCR5 chemokine
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connection between loss of CD45RA+ Tregs and increased levels of
IL-10 in severe COVID-19 patients, which may result in increasing
mortality rates in these patients (Wang et al., 2020). According to a
separate study, Treg levels were notably lower in COVID-19
patients with severe cases, particularly those with severe
symptoms (Qin et al., 2020). A study by Julika et al. also revealed
that IL-10-producing Treg levels were particularly high in severe
COVID-19 patients; the study also proved that Treg levels were
elevated in mild COVID-19 patients as well. The severity of the
disease may be linked to the production of IL-10 in certain tissues,
such as the lungs (Neumann et al., 2020). In a report, Yang et al.
described a patient with asymptomatic SARS-CoV-2 infection with
CD3+CD8-CD4+CD127-CD25+ Treg surface phenotypes, a higher
level of Tregs was present at day 7, a peak at day 22, and a
downward trend at day 28 compared to healthy controls. During
the early phase of asymptomatic infection, the proportion of
incompetent T cells is high, suggesting that Tregs are inhibiting
the activation and function of T cells (Impaired T cell functions
along with elevated activated Tregs at the early stage of 2
asymptomatic SARS-CoV-2 infection). In some COVID-19
patients without Foxp3, the levels of CD45RA+CCR7+ Tregs in
some COVID-19 patients decreased, while the levels of activated
CD45RA-CCR7+ Tregs increased (De Biasi et al., 2020). The T cells
of patients with COVID-19 are highly activated, Foxp3 expression
is inhibited, and hyperactive CD25+ Tregs proliferate quickly and
die before they become fully functional Tregs. Patients with
COVID-19 may suffer from an overactive immune system and
lung injury due to a reduction of Treg levels. The high frequency of
hyperactivated CD25+ T cells may cause immunothrombosis,
another symptom of COVID-19 severe manifestations (Kalfaoglu
et al., 2020; Stephen-Victor et al., 2020; McGonagle et al., 2020).
Another study found that severe COVID-19 patients had a higher
number of Tregs with higher levels of FoxP3 expression than mild,
recovered, or healthy controls. Furthermore, there is a higher
expression of PD-1 and T-bet on Tregs in severe COVID-19
patients. Additionally, the researchers found that IL-16 and IL-8
induce the Treg phenotype in COVID-19 patients (Galvan-Pena
et al., 2021). A recent study showed that CD4+ Foxp3+ regulatory T
cells activate dendritic cells to produce antigen-speciﬁc immunity
against emerging SARS-CoV-2 antigens (Uraki et al., 2021). In light
of the changes in Treg factors and their potential role in the
treatment of patients with COVID-19, Tregs will likely become a
novel target for the treatment of COVID-19, which should be
carefully examined in further experiments and clinical trials.
Th17 in COVID-19: Th17 is an IL-17-producing CD4+ Tcell subsets, which can be recognized by their production of
interleukin-17 (IL-17) (Saini et al., 2022). IL-17 is a potent
cytokine strongly associated with inﬂammatory processes and
exhibits robust effects on stromal cells throughout the body
(Tesmer et al., 2008). Research has shown that Th17 cells play a
critical role in defending against extracellular bacteria, fungi, and
autoimmune diseases by producing IL-17 (Yasuda et al., 2019)..
Activated antigen-presenting cells such as dendritic cells, which

regulating immune self-tolerance and various immune
responses (Sakaguchi et al., 2020). The anti-inﬂammatory and
tissue homeostasis properties of Treg cells go beyond
suppressing autoimmune diseases (Sakaguchi et al., 2008; Saini
et al., 2017). Various mechanisms are used by the Treg
population to inhibit innate and adaptive immunity (Saini
et al., 2018). These mechanisms include blocking antigenpresenting cell maturation via the CTLA-4 pathway, reducing
IL-2 availability to conventional T cells with constitutive
expression of the high-afﬁnity IL-2 receptor, and secreting
immunosuppressive molecules (IL-10, TGF-b, IL-35) (Tarique
et al., 2017; Tarique et al., 2017). In the context of acute viral
infection, medical research on Tregs in humans is limited.
Studies have, however, suggested that Treg cells are also
involved in viral infection immunopathology. These cells
suppress immunity-mediated mechanisms of tissue damage by
targeting immune-mediated mechanisms of tissue protection
and suppressing antiviral T cell responses (Robertson and
Hasenkrug, 2006; Li et al., 2008). Researchers have
demonstrated that Tregs possess protective properties against
virus-mediated tissue damage, including inﬂammation caused
by herpes simplex virus, HCV-induced liver damage, and
hepatitis C virus-induced cirrhosis (Claassen et al., 2010), as
well as encephalitis caused by coronaviruses (Anghelina et al.,
2009). In contrast, from experimental and clinical studies, it is
evident that Tregs are central to the pathophysiology of some
respiratory diseases like chronic obstructive pulmonary disease,
asthma, idiopathic pulmonary ﬁbrosis (IPF) (Krishnamoorthy
et al., 2012; Loebbermann et al., 2012; Singh et al., 2019).
However, inconsistent reports exist regarding the role of Treg
cells in COVID-19 infection.
It is unclear how T-regs regulate the antigen-speciﬁc immune
response to SARS Coronavirus 2 (SARS-CoV-2). According to
some studies, the number of Treg cells in COVID-19 has increased,
while others have revealed an unchanged or decreased number
(Chen et al., 2020; Tan et al., 2020). The number of regulatory
T cells (CD3+CD4+CD25+CD127low+), naïve regulatory T cells
(CD45RA+CD3+CD4+CD25+CD127low+), as well as induced
regulatory T cells (CD45RO+CD3+CD4+CD25+CD127low+) are
decreased in the circulation of COVID-19 patients as compared to
healthy controls (Qin et al., 2020). Furthermore, both mild and
severe COVID-19 patients had signiﬁcantly higher Treg cell
frequencies in lymphocytes. Interestingly, Treg cells from patients
with severe disease expressed a higher amount of CD25, further
supporting increased immunoregulatory activity by Tregs
(Tan et al., 2020). Among COVID-19 patients, Treg numbers
have been signiﬁcantly altered. Researchers found that both mild
and severe COVID-19 patients had reduced levels of expression of
CD4+ CD25+ CD127low Tregs and CD45RA+ Tregs. COVID-19
patients with severe disease had a much lower proportion of
CD45RA+ Tregs than those with moderate disease, while
moderate and severe COVID-19 patients with comparable
numbers of CD45RO+ Tregs (Chen et al., 2020). There may be a
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towards Th17 functional phenotype (De Biasi et al., 2020). It is
possible that severe cases of COVID-19 will cause a drastic
autoimmune response due to the lower proportion of Tregs. In
COVID-19 patients, it has been suggested that the overrepresentation of Th17/Treg may affect the levels of regulatory
cytokines (IL-4, IL-10, TGF-b, and IL-35) and the ability to
tolerate self-antigens, ultimately leading to autoimmune
inﬂammation (Qin et al., 2020). Huang et al. also observe an
increase in IL-17 in COVID-19 patients that is more prominent
in intensive care compared to non-intensive care and controls
(Huang et al., 2020), and Zumla et al. postulate that blocking IL17 could improve respiratory distress syndrome-related
mortality and apparent aberrant immune response in COVID19 patients (Zumla et al., 2020). Though blocking IL-17 may
decrease Th1 mediated inﬂammation, SARS-CoV-2 also appears
to increase Th2 cytokine production (IL-4 and IL-10) that
suppress Th1/Th17 mediated inﬂammation (Huang et al.,
2020). In light of these ﬁndings, further investigation into the
mechanisms underlying the action of IL-17 as a possible
COVID19 therapeutic target is essential.
NKT cells in COVID-19: Natural killer T (NKT) is a
heterogenous group of non-conventional T cells. In addition to
having the properties of both T cells and natural killer cells, NKT
cells also share aspects of both categories. This group of cells
recognizes the non-polymorphic CD1d molecule, which presents
antigens by binding to lipids and glycolipids of both self and foreign
origin. T cells in peripheral blood make up only about 1% of the
total T cells (Godfrey et al., 2004). There are two types of natural
killer T cells (NKTs): type I and type II NKTs. Type I NKT cells are
more commonly called invariant NKT (iNKT) and it recognizes
glycolipid antigens contained within CD1d molecules (Pellicci et al.,
2020). Additionally, proinﬂammatory cytokines produced during
an infection can activate iNKT cells (Slauenwhite and Johnston,
2015). An NKT cell that responds to lipid antigens belongs to type
II. It is CD1d-restricted. Researchers have found that type II NKT
cells are able to recognize hydrophobic peptides presented on CD1d
as well as lipid antigens. They are a distinct population of cells with
immune-regulatory capabilities that circulate and reside in tissues.
Evidence suggests they play a role in regulating immunity to
pathogens/tumors, as well as in autoimmune and metabolic
diseases (Dhodapkar and Kumar, 2017; Singh et al., 2018).
A study has shown that in mild or moderate cases of
COVID-19, the number of CD160+ NKT cells increases,
which is associated with a quicker resolution of the infection
by direct cytotoxicity. There was also signiﬁcant enrichment for
the FCGR3A gene in this cluster, which suggests that it could
play a role in antibody-dependent cytotoxicity. In severe cases of
COVID-19, the CD160 cluster was noticeable absent (Zhang
et al., 2020). There has been evidence that circulating iNKT cells
are activated by IL-18 in severe cases of COVID-19 (Jouan et al.,
2020), IL-18 cytokine is associated with T cell activation during
viral infections (Tsai et al., 2015). iNKT cells are also seen to be
declining along with IFN-g production by iNKT cells in severe

secrete IL-23 as a result of taking up and processing pathogens,
activate Th17 cells. There is evidence that many proinﬂammatory cytokines and chemoattractant are elevated in
COVID-19 patients, including IL-1b, IL-6, IL17, TNF-a, GMCSF, and IFN-g. These pro-inﬂammatory cytokines and
chemoattractant are related to Th17-mediated responses (Wu
and Yang, 2020). A pro-inﬂammatory cytokine up-regulation
during inﬂammation leads to polarization of Th17 cells
(Pourgholaminejad et al., 2016).
COVID-19 patients with severe complications have also
been reported to have higher numbers of proinﬂammatory
Th17 cells in peripheral blood; the proinﬂammatory cytokine
IL-17 may be a potential immunologically plausible modiﬁable
target that could prevent ARDS, although more research is
needed to support this (de Candia et al., 2021). In response to
upregulation of Th17 cytokines, especially IL-17 and IL-22,
mucin, ﬁbrinogen and serum amyloid A are produced. There
is a possibility that oedema formation in the mucosa of the
respiratory tracts of COVID-19 patients is caused by systemic
inﬂammation caused by Th17 (Wu and Yang, 2020). Apart from
the proinﬂammatory cytokines, IL-6 also affects T cell
polarization by stimulating the Th17 pathway and inhibiting
TGF-b induced Treg production (Kimura and Kishimoto, 2010).
A study by Hou et al. revealed that excessive IL-6 level promotes
the formation of Th17 cells, and the IL-6 and IL-17 released
from the transformed Th17 cells promote viral persistence by
inhibiting apoptosis of virus-infected cells (Hou et al., 2014). In
the case of inﬂuenza virus infection, increased neutrophils are
found in the airspace following IL-17 production, which
contributes to acute lung injury with a high mortality rate
(Crowe et al., 2009). In several human diseases, recent
research showed that IL-17 functions were important for
suppressing viral infections and minimizing tissue pathology
in different settings of viral infection (Ma et al., 2019). A study
suggested that COVID-19 patient with pneumonia produced
more in vitro IL-17, which boosted the inﬂammation response
and activated neutrophils in vitro CD4+ and CD8+ T cells
produced more of IL-17 in patients with pneumonia.
Furthermore, peripheral blood cells from patients expressed
less CCR6 and more CD161, both of which are characteristic
of TH17 and mucosal associated invariant T (MAIT) cells,
respectively. A higher IL-17 production was observed in lung
cells compared to peripheral blood cells. Overall, these ﬁndings
support the importance of IL-17 in COVID-19 and suggest that
biological drugs, which are already available, might be useful in
developing novel therapeutic approaches (De Biasi et al., 2020)..
MERS-CoV patients also showed elevated levels of
proinﬂammatory molecules, including IFN-g, TNF-a, IL-15,
and IL-17, indicating a Th1/Th17 response (Mahallawi et al.,
2018). COVID-19 is heavily inﬂuenced by IL-17, which recruits
and activates neutrophils, which migrate to the lungs and
participate in pathogenesis. They demonstrate that activation
of T cells in COVID-19 patients is signiﬁcantly skewered
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understand gd T cell and COVID-19 relationships, researchers
need to investigate the cytokine release syndrome (CRS), often
called cytokine storm and ﬁbrosis, two of the most serious
complications suffered by COVID-19 patients. A number of
cytokines are produced and secreted by gd T cells, including
IFN-g, TNF-a, IL-6, and IL-17 (Figure 3). Besides interacting
with other immune cells, they also perform cytolysis using
cytotoxic perforin and granzyme (Battistini et al., 2005).
Moreover, gd T cells are capable of defending against viral
infection by secreting IFN-g, up-regulating NKG2D, and
producing perforin, granzyme B, and FasL (Xue et al., 2017).
The gd cells display increased activation and preferentially
produce IL-17A while avoiding producing IFN-g (Rijkers et al.,
2020). Researchers found that endotracheal aspirates contain
higher concentrations of inﬂammatory cytokines like IL1b, IL-6,
and IFN-g than matched blood samples. They also found the
presence of gd T cells with heightened levels of activation in
COVID-19 sample aspirates (Jouan et al., 2020). There are
strong indications that gd T cells play an important role in the
immune response of COVID-19 in the most resistant
population. There is no doubt that gd T cells have great
potential in helping the ﬁght against the SARS-Cov-2
pandemic, but further research is needed.
MR1-restricted mucosal-associated invariant T (MAIT) cells
in COVID-19: The major histocompatibility complex class Irelated molecule (MR1) recognizes vitamin B metabolites from
microbes at mucosal sites and plays a putative role in
antimicrobial immunity (Treiner et al., 2003). The number of
MAIT cells varies widely among healthy individuals, with up to
half of all T cells in the liver and 2 to 5% of T cells in the blood
containing MAIT cells (Godfrey et al., 2015). MAIT cells are
frequently found in low numbers in patients with viral infections
(Leeansyah et al., 2013; Barathan et al., 2016; Paquin-Proulx
et al., 2017). The cytokines IL-12 and IL-18 have been shown to
activate MAIT cells in a TCR-independent manner, though they
are not directly activated by viruses (Ussher et al., 2014).
Proinﬂammatory cytokines such as IFN-g, TNF-a, and IL-17
are rapidly produced by activated MAIT cells (van Wilgenburg
et al., 2016).
There is evidence that MAIT cells can be activated by IL-18
in a non-receptor-dependent manner during SARS-CoV-2
infection, since CD69 expression on MAIT cells correlates
with high plasma IL-18 levels (Jouan et al., 2020). A decrease
in circulating MAIT cells was observed during mild and
moderate infections, which is thought to reﬂect the
recruitment of these cells into the airways and their activationinduced death (Flament et al., 2021). Despite the underlying
causes of COVID-19 and regardless of the patient’s course of
disease, MAIT cells were highly activated and produced large
amounts of proinﬂammatory cytokines such as IL-17A and
TNF-a. The cytokines IL-17A and TNF-a, as well as granzyme
B and perforin were not upregulated in response to MAIT cellspeciﬁc in vitro stimulation. Researchers have observed altered

cases of COVID-19. iNKT cells from patients in intensive care
units displayed increased CD69 and PD-1 expression at day 15,
but PD-1 was still highly expressed on iNKT cells (Jouan et al.,
2020). Interestingly, another study found reduced levels of NKT
(CD3+ CD56+) cells in patients with severe disease (Zingaropoli
et al., 2021), but this ﬁnding is inconsistent with those from
other studies (Zhang et al., 2020; Mazzoni et al., 2020). It is
fascinating that CD3+CD56+ T cells are associated with
COVID-19 severity, even though they are immensely unlikely
to be CD1d-restricted NKT cells (Kreutmair et al., 2021). The
CD3+CD56+ T cells are heterogeneous, with a variety of nonMHC-restricted nonconventional T cells such as mucosal
associated invariant T (MAIT) cells, as well as gd T cells
(Godfrey et al., 2015). CD56-expressing cells may also include
T cells associated with cytotoxicity, like CD8+ T cells (Van
Acker et al., 2017). A deeper analysis of this population may aid
in understanding how the immune system responds to severe
COVID-19.
gd T cells in COVID-19: gd T cells are engaged in the
adaptive immune response as well as the early immunological
response to infections or malignant transformation (Saini et al.,
2018). Despite accounting for approximately 0.5-5 percent of
circulating T cells in homeostatic settings, gd T cells are potent
effector cells (Tarique et al., 2017).Research into the involvement
of T cells so far has largely focused on T cells. Thus, a limited
amount of information is available regarding the involvement of
gd T cells. It’s important to note ﬁrst and foremost that the
lymphopenia being reported affects abT cells as much as gd T
cells (Lei et al., 2020; Odak et al., 2020). An interesting ﬁnding
was that the patients with the most severe symptoms had the
least amount of T cells in their body (Rijkers et al., 2020). The
question arises, then, whether the number of gd T cells in
patients is a good indicator of disease severity. Furthermore,
there appears to be a signiﬁcant change in the phenotype of gd T
cells in patients. These changes are the subject of conﬂicting
reports. In one study, both percentages and absolute numbers
indicate a shift towards nave behavior (Odak et al., 2020). Over
the course of two weeks, in contrast, a shift towards an effector
phenotype was observed in a different study with signiﬁcantly
less patients. There is evidence that a lymphopenia has been
observed, similar to what has been described in gd T cells, along
with an overall reduction of the naive phenotype. COVID 19
patients’ increased activation marker CD25 also supports this
conclusion (Carter et al., 2020). In addition, CD69 and PD-1 are
highly expressed on gd T-cells, indicating strong evidence that
the immune system is working (Chen and John Wherry, 2020).
Both the frequency and absolute number of naive (CD45RA
+CD62L+) gd T cells were elevated in blood in mild and severe
cases of COVID-19, whereas the number of effector (CD45RACD62L+) gd T cells decreased proportionately. Several
researchers hypothesized that effector-like gd T cells could be
recruited to the lungs of COVID-19 patients, where they would
help combat the infection (Odak et al., 2020). In order to better
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FIGURE 3

T cells in severe COVID-19: presence and activation.: Numbers of CD4 and CD8 decreased in peripheral blood (lymphopenia) while activated
CD4 and CD8 cells are increased in lung secernated excessive amount of TNF-a and IFN-g which damaged lung and inhibits function of Tregs.
IL-17 secreting Th17 cells and follicular helper T (Tfh) cells increased in peripheral blood of COVID-19 patients, however there are conﬂicting
ﬁnding in case of Tregs. The number of NKT, MAIT, and gd T cells decreases in peripheral blood and is detected in lung aspirates with
heightened levels of activation, as evaluated by CD69 and PD-1. Activated conventional and unconventional T cells in the lung may secrete
multiple inﬂammatory cytokines such as IL-17A, IL-6, TNF-a, and IFN-g that contribute to the cytokine milieu and/or disease pathology.

CD69+CXCR3- MAIT cells replicated this circulating
phenotype, which was found to be the major source of IL-17A
(Parrot et al., 2020). Both mild and severe COVID-19 cases have
been associated with higher levels of IL-17A, with the highest
levels observed in severe cases. IL-17 activates inﬂammatory
pathways that can cause tissue damage and aggravate disease;
therefore, it is likely to contribute to the development of
COVID-19 (Fadlallah et al., 2021). There were reduced
frequency and an activated phenotype of circulating MAIT
cells in COVID-19 patients regardless of disease severity, as
demonstrated by high levels of IL-17A, TNF-a, CD38, CD69,
and HLA-DR expression (Deschler et al., 2021).
These results imply a pathogenic role for MAIT cells in
COVID-19 patients, with a reduced number of cells in the
periphery and increased numbers in the lung and an earlier
active phenotype correlated with a poorer outcome. The
activation of MAIT cells has also been associated with vaccine
immunity as MAIT cells boost CD8 T cell response to adenoviral
vaccines. The MAIT cell effector responses may have different
impacts depending on the disease stage, but more research is
needed to dissect these differing contributions to antiviral
immunity in the COVID-19 setting.

MAIT cell cytokine expression proﬁles in COVID-19, as well as
disruptions in their anti-bacterial and antiviral function and thus
contributed to the understanding of the COVID-19
immunopathogenesis (Deschler et al., 2021). Among COVID19 patients, a higher frequency of MAIT cells was observed in
endotracheal aspirates than matched blood samples (Jouan et al.,
2020). There was also an inverse correlation between the
frequency of MAIT cells and the level of IL-17C (proinﬂammatory cytokine) in plasma of COVID-19 patients.
SARS-CoV-2 infections were associated with both MAIT cell
recruitment and increased lung epithelial inﬂammation,
supporting the possible link between these features (Parrot
et al., 2020). A report suggested that MAIT cells also expressed
CXCR3 (Saha et al., 2013), several studies have shown an
increase in expression of early activation marker CD69 on
MAIT cells and a decrease in expression of the homing
marker CXCR3 in mild and severe cases of COVID-19 (Parrot
et al., 2020; Flament et al., 2021; Deschler et al., 2021). As
opposed to conventional CD4+ and CD8+ T cells, MAIT cells
were characterized by higher levels of CD69 expression and
lower levels of CXCR3, and CXCR3 expression on MAIT cells
was inversely correlated with CD69 expression. In the airways,
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Conclusion
SARS-CoV-2 infection triggers an inﬂammatory response
that can lead to debilitating illness and cytokine storms, resulting
in cytokine storm and debilitating health condition. The
emerging studies into various conventional and nonconventional T cell subsets that are involved in both the
pathogenesis and resolution of COVID-19 reveal interesting
and intriguing information regarding how these cells are
involved in both the pathogenesis and resolution of the
disease. It remains unclear how the underlying mechanisms
act and what stage-dependent functions they perform. A variety
of T cell subsets have been shown to become activated in
response to viral infections, including COVID-19, and to have
antiviral capabilities, although it remains to be seen whether
such functions can be successfully exploited for therapy. The loss
or dysfunction of T cells or the overactivation of T cells may also
increase the susceptibility to other microbial infections, as well as
autoimmunity, which may result in serious complications,
including sepsis, as well as understanding how SARS-CoV-2 is
transmitted. To better understand T cell subsets, which are
important for both innate and adaptive immunity, we need to
learn more about their complex antimicrobial effector functions.
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